APTO Stock Price, Aptose Biosciences Inc Quote, Chart

Market Summary

USD1.24+0.08

Market Closed

6.90%

APTO Stock Price

View Fullscreen

APTO RSI Chart

APTO Valuation

Market Cap

19.5M

Price/Earnings (Trailing)

-0.38

Price/Free Cashflow

-0.44

APTO Price/Sales (Trailing)

APTO Profitability

Return on Equity

1.8K%

Return on Assets

-394.23%

Free Cashflow Yield

-228.96%

APTO Fundamentals

APTO Earnings

Earnings (TTM)

-51.2M

Earnings Growth (Yr)

-19.55%

Earnings Growth (Qtr)

-4.44%

Breaking Down APTO Revenue

Last 7 days

0.8%

Last 30 days

-17.3%

Last 90 days

-37.4%

Trailing 12 Months

-82.5%

How does APTO drawdown profile look like?

APTO Financial Health

Current Ratio

0.78

APTO Investor Care

Shares Dilution (1Y)

153.50%

Diluted EPS (TTM)

-7.85

Tracking the Latest Insider Buys and Sells of Aptose Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 22, 2023	seizinger bernd r.	bought	53,380	3.14	17,000	-
Jan 19, 2023	ledru philippe	acquired	-	-	100,000	chief commercial officer
Jan 19, 2023	bejar rafael	acquired	-	-	100,000	sr. vp, chief medical officer
Jan 19, 2023	rice william g.	acquired	-	-	150,000	chair, president & ceo
Jan 19, 2023	payne fletcher	acquired	-	-	100,000	sr vp & chief fin. officer
Sep 19, 2022	rice william g.	bought	6,834	0.6834	10,000	chair, president & ceo
Sep 19, 2022	payne fletcher	bought	6,775	0.6775	10,000	sr vp & chief fin. officer
Jun 06, 2022	rice william g.	bought	9,681	0.9681	10,000	chair, president & ceo
Dec 20, 2021	burger denis r	bought	14,490	1.449	10,000	-
Dec 16, 2021	platzer erich	bought	137,900	1.379	100,000	-

Which funds bought or sold APTO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-732	1,381	-%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	-81.00	153	-%
Apr 12, 2024	Gleason Group, Inc.	unchanged	-	-1,070	2,019	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	unchanged	-	-65.00	635	-%
Feb 16, 2024	DRW Securities, LLC	unchanged	-	-154,214	1,505,790	0.02%
Feb 15, 2024	Nantahala Capital Management, LLC	added	76.04	228,118	610,270	0.02%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-92.86	-3,666	254	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	256	106,718	155,306	-%
Feb 14, 2024	Royal Bank of Canada	added	838	15,000	17,000	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	39,340	39,340	-%

Are Funds Buying or Selling APTO?

Are funds buying APTO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APTO

No. of Funds

Unveiling Aptose Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	1.5%	120,132	SC 13G/A
Feb 05, 2024	hanmi pharmaceutical co., ltd.	22.17%	2,989,415	SC 13D/A
Sep 12, 2023	hanmi pharmaceutical co., ltd.	12.07%	884,152	SC 13D
Feb 14, 2023	nantahala capital management, llc	6.6%	6,052,867	SC 13G/A
Jan 17, 2023	fletcher aaron g.l.	3.6%	3,311,458	SC 13G
Feb 14, 2022	nantahala capital management, llc	8.5%	7,604,693	SC 13G/A
Feb 11, 2022	orbimed capital llc	0.00%	0	SC 13G/A
Aug 10, 2021	wilson donald r. jr.	993%	8,888,275	SC 13G/A
Feb 17, 2021	consonance capital management lp	-	0	SC 13G/A
Feb 16, 2021	consonance capital management lp	-	0	SC 13G/A

Recent SEC filings of Aptose Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	SC 13D/A	13D - Major Acquisition
Apr 05, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	4	Insider Trading
Feb 07, 2024	4	Insider Trading

Peers (Alternatives to Aptose Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Aptose Biosciences Inc News

Latest updates

Aptose Biosciences Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-37.8%	13.00	21.00	27.00	39.00	51.00	57.00	65.00	73.00	83.00	97.00	106	115	126	135	85.00	93.00	100	32.00	38.00	20.00	17.00
Current Assets	-39.5%	12.00	20.00	25.00	38.00	50.00	57.00	64.00	72.00	82.00	96.00	105	114	125	134	84.00	91.00	99.00	31.00	36.00	18.00	16.00
Cash Equivalents	-41.1%	9.00	16.00	8.00	23.00	37.00	28.00	40.00	37.00	39.00	75.00	83.00	87.00	117	100	54.00	60.00	80.00	21.00	27.00	17.00	15.00
Net PPE	-10.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	21.3%	16.00	13.00	13.00	13.00	13.00	10.00	9.00	7.00	8.00	9.00	8.00	6.00	7.00	6.00	6.00	5.00	7.00	5.00	4.00	4.00	3.00
Current Liabilities	23.3%	15.00	12.00	12.00	12.00	12.00	10.00	9.00	7.00	8.00	8.00	8.00	5.00	7.00	5.00	5.00	4.00	6.00	4.00	3.00	3.00	3.00
Shareholder's Equity	-137.3%	-2.90	8.00	14.00	26.00	38.00	47.00	55.00	65.00	74.00	89.00	98.00	109	119	129	79.00	87.00	94.00	27.00	34.00	15.00	14.00
Retained Earnings	-2.4%	-515	-503	-492	-478	-464	-454	-444	-433	-422	-398	-386	-373	-357	-342	-329	-313	-301	-294	-287	-281	-275
Additional Paid-In Capital	0.6%	72.00	72.00	71.00	70.00	69.00	68.00	67.00	66.00	64.00	61.00	60.00	57.00	51.00	46.00	46.00	39.00	35.00	35.00	34.00	34.00	33.00
Shares Outstanding	5.3%	8.00	8.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-
Float	-	-	-	30.00	-	-	-	68.00	-	-	-	293	-	-	-	478	-	-	-	143	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	12.2%	-9,254	-10,536	-13,503	-11,302	-8,651	-6,979	-7,047	-9,645	-16,044	-8,059	-8,825	-10,376	-10,348	-8,270	-7,164	-8,111	-6,231	-5,184	-5,269	-4,874	-5,502
Share Based Compensation	-31.4%	411	599	769	1,874	861	1,053	779	2,514	2,314	1,828	2,164	6,643	4,431	4,905	7,701	4,401	562	504	568	662	581
Cashflow From Investing	-85.1%	1,933	12,953	-1,960	-2,960	17,573	-5,078	10,066	7,505	-20,010	-185	4,999	-20,012	27,967	-4,398	1,479	-12,427	-8,278	-1,042	-8,026	-24.00	-86.00
Cashflow From Financing	-82.6%	854	4,902	1,104	50.00	51.00	21.00	29.00	15.00	66.00	-	85.00	75.00	42.00	58,283	46.00	436	73,640	17.00	23,613	6,178	5,839

APTO Income Statement

2023-12-31

Consolidated Statements of Loss and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 0	$ 0
Expenses:
Research and development, related party	3,492	3,556
Research and development	33,273	24,532
General and administrative	15,591	14,514
Operating expenses	52,356	42,602
Other income :
Interest income	1,151	788
Foreign exchange loss	(2)	(9)
Total other income	1,149	779
Net loss	(51,207)	(41,823)
Other comprehensive loss:
Unrealized gain (loss) on securities available-for-sale securities	2	(2)
Total comprehensive loss	$ (51,205)	$ (41,825)
Basic loss per common share	$ (7.58)	$ (6.8)
Diluted loss per common share	$ (7.58)	$ (6.8)
Weighted average number of common shares outstanding used in the calculation of basic per share (in shares)	6,755	6,151
Weighted average number of common shares outstanding used in the calculation of diluted loss per share (in shares)	6,755	6,151

APTO Balance Sheet

2023-12-31

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,252	$ 36,970
Investments		9,989
Prepaid expenses	2,042	2,303
Other current assets	600	257
Total current assets	11,894	49,519
Non-current assets:
Property, plant and equipment, net	152	211
Right-of-use assets, operating leases	943	1,297
Total non-current assets	1,095	1,508
Total assets	12,989	51,027
Current liabilities:
Accounts payable to related party	2,554	2,984
Accounts payable	3,492	3,342
Accrued liabilities to related party		572
Accrued liabilities	8,829	5,085
Current portion of lease liability, operating leases	394	301
Total current liabilities	15,269	12,284
Non-current liabilities:
Lease liability, operating leases	621	1,002
Total liabilities	15,890	13,286
Shareholders' equity:
Common shares, no par value, unlimited authorized shares, 7,942,363 and 6,157,749 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	444,806	437,520
Additional paid-in capital	72,146	68,869
Accumulated other comprehensive loss	(4,316)	(4,318)
Deficit	(515,537)	(464,330)
Total shareholders’ equity	(2,901)	37,741
Total liabilities and shareholders’ equity	$ 12,989	$ 51,027

About Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

CEO	Dr. William G. Rice Ph.D.
WEBSITE	aptose.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Aptose Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Aptose Biosciences Inc? What does APTO stand for in stocks?

APTO is the stock ticker symbol of Aptose Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptose Biosciences Inc (APTO)?

As of Fri Apr 26 2024, market cap of Aptose Biosciences Inc is 19.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers. The fair value of Aptose Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptose Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APTO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptose Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether APTO is over valued or under valued. Whether Aptose Biosciences Inc is cheap or expensive depends on the assumptions which impact Aptose Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APTO.

What is 5 year return on Aptose Biosciences Inc's stock?

In the past 10 years, Aptose Biosciences Inc has provided -0.35 (multiply by 100 for percentage) rate of return.